Allspring Global Investments Holdings LLC Has $59.21 Million Stake in ADMA Biologics Inc (NASDAQ:ADMA)

Allspring Global Investments Holdings LLC grew its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 7.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,048,946 shares of the biotechnology company's stock after buying an additional 207,097 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 1.29% of ADMA Biologics worth $59,211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in ADMA. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter valued at about $35,000. Vision Financial Markets LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter valued at about $51,000. Farther Finance Advisors LLC lifted its holdings in shares of ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,505 shares during the last quarter. AlphaQuest LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter valued at about $84,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of ADMA Biologics during the 4th quarter valued at about $85,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 1.3%

ADMA opened at $18.16 on Monday. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $31.50. The firm has a market cap of $4.34 billion, a P/E ratio of 21.36 and a beta of 0.47. The business has a 50 day moving average price of $20.57 and a 200 day moving average price of $18.74. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same quarter last year, the firm earned $0.08 earnings per share. The firm's quarterly revenue was up 40.2% compared to the same quarter last year. Research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on ADMA. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th. Finally, Raymond James Financial boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th.

Insider Activity

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director now directly owns 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Lawrence P. Guiheen sold 7,779 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the sale, the director now owns 114,830 shares in the company, valued at $2,333,345.60. This trade represents a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 464,621 shares of company stock worth $9,644,269. Company insiders own 3.70% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.